Abstract：There are more than 70 species of flaviviruses, including Zika virus, Dengue virus and Japanese encephalitis virus, and more than 33 species are known to be capable of infecting humans. Only three flavivirus vaccines have been approved, and there is a lack of safe and effective vaccines for most flaviviruses. Adenovirus-vectored vaccines have high safety, low cost, and convenience to store and transport. Currently, two adenovirus-vectored Zika vaccines are under early clinical trials, and adenovirus-vectored vaccines for Dengue virus, Japanese encephalitis virus, West Nile virus and yellow fever virus are still in the phase of animal experiment. In the development of adenovirus-vectored flavivirus vaccines, there are still problems of pre-existing immunity to adenovirus, the insufficient immunogenicity of adenovirus vectors and the antibody-dependent enhancement effects among flavivirus. Based on relevant publications from January 2006 to June 2023, this article reviews the current status, challenges and solutions of the research into adenovirus-vectored flavivirus vaccines, so as to provide the reference for the development of relevant vaccines.
[1] LURIA-PEREZ R,SANCHEZ-VARGAS L A,MUNOZ-LOPEZ P,et al.Mucosal vaccination:a promising alternative against flaviviruses[J/OL].Front Cell Infect Microbiol,2022,12[2023-08-02].https://doi.org/10.3389/fcimb.2022.887729. [2] FERNANDEZ-GARCIA M D,MAZZON M,JACOBS M,et al.Pathogenesis of flavivirus infections:using and abusing the host cell[J].Cell Host Microbe,2009,5(4):318-328. [3] 陈浩威,崔旻.黄病毒入侵中枢神经系统的分子机制研究进展[J].华中农业大学学报,2021,40(4):85-93. [4] GEBRE M S,BRITO L A,TOSTANOSKI L H,et al.Novel approaches for vaccine development[J].Cell,2021,184(6):1589-1603. [5] AFKHAMI S,KANG A,JEYANATHAN V,et al.Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19[J/OL]. Curr Opin Virol,2023,61[2023-08-02].https://doi.org/10.1016/j.coviro.2023.101334. [6] WANG S, LIANG B, WANG W Q,et al.Viral vectored vaccines:design,development,preventive and therapeutic applications in human diseases[J/OL].Signal Transduct Target Ther,2023,8(1)[2023-08-02].https://doi.org/10.1038/s41392-023-01408-5. [7] SALISCH N C,STEPHENSON K E,WILLIAMS K,et al.A double-blind,randomized,placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-Zika virus vvaccine[J].Ann Intern Med,2021,174(5):585-594. [8] LOPEZ-CAMACHO C, ABBINK P, LAROCCA R A, et al.Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors[J/OL].Nat Commun,2018,9(1)[2023-08-02].https://doi.org/10.1038/s41467-018-04859-5. [9] HASSAN A O,DMITRIEV I P,KASHENTSEVA E A,et al.A gorilla adenovirus-based vaccine against Zika virus induces durable immunity and confers protection in pregnancy[J].Cell Rep,2019,28(10):2634-2646. [10] ABBINK P,LAROCCA R A,DE LA BARRERA R A,et al.Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys[J].Science,2016,353(6304):1129-1132. [11] 韩雨旋. 基于黑猩猩重组腺病毒载体的寨卡病毒疫苗研究[D].海口:海南医学院,2019. [12] HALSTEAD S B.Pathogenesis of dengue:challenges to molecular biology[J].Science,1988,239(4839):476-481. [13] RAVIPRAKASH K,WANG D,EWING D, et al.A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus[J].J Virol,2008,82(14):6927-6934. [14] SHOUSHTARI M,ROOHVAND F,SALEHI-VAZIRI M,et al.Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses[J/OL].Hum Vaccin Immunother,2022,18(5)[2023-08-02].https://doi.org/10.1080/21645515.2022.2079323. [15] KHANAM S,PILANKATTA R,KHANNA N,et al.An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity[J].Vaccine, 2009,27(43):6011-6021. [16] SCHEPP-BERGLIND J,LUO M,WANG D,et al.Complex adenovirus-mediated expression of West Nile virus C,PreM,E,and NS1 proteins induces both humoral and cellular immune responses[J].Clin Vaccine Immunol,2007,14(9):1117-1126. [17] APPAIAHGARI M B,SAINI M,RAUTHAN M,et al.Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis[J].Microbes Infect,2006,8(1):92-104. [18] BASSI M R,LARSEN M A,KONGSGAARD M,et al.Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe Yellow fever virus infection in mice[J/OL].PLoS Negl Trop Dis,2016,10(2):[2023-08-02].https://doi.org/10.1371/journal.pntd.0004464. [19] ROBERTS D M,NANDA A,HAVENGA M J,et al.Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity[J].Nature,2006,441(7090):239-243. [20] CROYLE M A.AMI P,TRAN K N,et al.Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice[J/OL].PLoS One,2008,3(10)[2023-08-02].https://doi.org/10.1371/journal.pone.0003548. [21] JEYANATHAN M,FRITZ D K,AFKHAMI S,et al.Aerosol delivery, but not intramuscular injection,of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans[J/OL].JCI Insight,2022,7(3)[2023-08-02].https://doi.org/10.1172/jci.insight.155655. [22] COUGHLAN L.Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines[J/OL].Front Immunol,2020,11[2023-08-02].https://doi.org/10.3389/fimmu.2020.00909. [23] BULLARD B L, CORDER B N, GORMAN M J,et al.Efficacy of a T cell-biased adenovirus vector as a Zika virus vaccine[J/OL]. Sci Rep, 2018, 8(1)[2023-08-02].https://doi.org/10.1038/s41598-018-35755-z. [24] LOGUNOV D Y,DOLZHIKOVA I V,ZUBKOVA O V,et al.Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations:two open,non-randomised phase 1/2 studies from Russia[J].Lancet,2020,396(10255):887-897. [25] LOGUNOV D Y,DOLZHIKOVA I V,SHCHEBLYAKOV D V,et al.Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine:an interim analysis of a randomised controlled phase 3 trial in Russia[J].Lancet,2021,397(10275):671-681. [26] AFKHAMI S,D'AGOSTINO M R,ZHANG A,et al.Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2[J].Cell,2022,185(5):896-915. [27] BROWN J A,SINGH G,ACKLIN J A,et al.Dengue virus immunity increases Zika virus-induced damage during pregnancy[J].Immunity,2019,50(3):751-762. [28] CHEN D,DUAN Z L,ZHOU W H,et al.Japanese encephalitis virus-primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis[J/OL].J Exp Med,2020,217(9)[2023-08-02].https://doi.org/10.1084/jem.20192152. [29] KATZELNICK L C,GRESH L,HALLORAN M E,et al.Antibody-dependent enhancement of severe dengue disease in humans[J].Science, 2017,358(6365):929-932. [30] DAI L, XU K, LI J, et al.Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch[J].Nat Immunol,2021,22(8):958-968.
